Novo Nordisk targets over five blockbuster drugs by 2030
CEO Mike Doustdar said at Novo Nordisk’s Capital Markets Day in London the company aims to launch more than five blockbuster drugs by 2030 and deliver more than 150 billion Danish crowns in pipeline sales in 2035.